Clinical Trials
21 trialsNCT05403541 2026-06-05
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Active not recruiting
NCT07217587 2026-06-05
EPIC
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06392386 2026-06-04
ADAPT Jr SC
argenx
Phase 2/3 Recruiting
NCT07284420 2026-06-03
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
argenx
Phase 2 Recruiting
NCT07622342 2026-06-03
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2 Not yet recruiting
NCT06744920 2026-06-01
RELIEVE
Novartis
Phase 3 Recruiting
NCT06987539 2026-05-29
THYME
Amgen
Phase 2 Recruiting
NCT04980495 2026-05-27
ADAPT NXT
argenx
Phase 3 Completed
NCT06517758 2026-05-27
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Novartis
Phase 3 Recruiting
NCT06958939 2026-05-27
The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis
Tang-Du Hospital
Phase 1 Active not recruiting
NCT06463587 2026-05-22
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3 Recruiting
NCT07039916 2026-05-22
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Phase 3 Recruiting
NCT07246564 2026-05-22
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
UCB Pharma
Phase 4 Recruiting
NCT07596784 2026-05-19
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.
Phase 3 Not yet recruiting
NCT07596901 2026-05-19
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Aurinia Pharmaceuticals Inc.
Phase 1/2 Recruiting
NCT06359041 2026-05-18
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Cabaletta Bio
Phase 1/2 Active not recruiting
NCT06680037 2026-05-18
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
Phase 1 Recruiting
NCT07501702 2026-05-18
ETNA
Vertex Pharmaceuticals Incorporated
Phase 2 Recruiting
NCT07593911 2026-05-18
ArchAid-002
Beijing GoBroad Hospital
Phase NA Not yet recruiting
NCT04524273 2026-05-15
MINT
Amgen
Phase 3 Active not recruiting
NCT06193889 2026-05-15
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
Phase 2/3 Recruiting